// App-Quantinova.ai

P618 : SECOND-GENERATION CD19 TARGETING TRI-SPECIFIC KILLER ENGAGER DRIVES ROBUST NK CELL FUNCTION AGAINST B CELL MALIGNANCIES

Researchers

Presenter

  • Jeffrey Miller

Principal Investigators

  • Behiye Kodal

  • Peter Hinderlie

  • Daniel Vallera

  • Greg Berk

  • Veronika Bachanova

  • Martin Felices

Medical Centers

  • Medicine,University of Minnesota,Minneapolis,Stati Uniti

  • GT Biopharma,Brisbane,Estados Unidos

  • GT Biopharma,Brisbane,Verenigde Staten

  • Radiation Oncology,University of Minnesota,Minneapolis,Estados Unidos

  • GT Biopharma,Brisbane,Stati Uniti

  • Medicine,University of Minnesota,Minneapolis,Stati Uniti

  • GT Biopharma,Brisbane,United States

  • Medicine,University of Minnesota,Minneapolis,Stati Uniti

  • Medicine,University of Minnesota,Minneapolis,Vereinigte Staaten

  • GT Biopharma,Brisbane,USA

  • Medicine,University of Minnesota,Minneapolis,Vereinigte Staaten

  • GT Biopharma,Brisbane,Verenigde Staten

  • Radiation Oncology,University of Minnesota,Minneapolis,Estados Unidos

  • GT Biopharma,Brisbane,États-unis

  • Medicine,University of Minnesota,Minneapolis,Stati Uniti

  • Radiation Oncology,University of Minnesota,Minneapolis,Estados Unidos

  • Radiation Oncology,University of Minnesota,Minneapolis,Estados Unidos

  • University of Minnesota, Minneapolis, MN, United States

  • Radiation Oncology,University of Minnesota,Minneapolis,Estados Unidos

  • Medicine,University of Minnesota,Minneapolis,Vereinigte Staaten

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B cell lymphomas

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Natural Killer cells

  • Cluster of Differentiation 5

  • Interleukin-15

Drug/Treatment

  • Rituximab

  • IL-15

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved